Opinion|Videos|May 12, 2025
Factors Contributing to Higher Incidence and Worse Outcomes of mHSPC in Black Men
Author(s)Quoc-Dien Trinh, MD, MPH
A panelist discusses how the differences in prostate cancer among Black men are multifactorial, including biological differences in risk alleles, social determinants of health, and limited access to care and clinical trials.
Advertisement
Episodes in this series
Multifactorial Causes of Racial Disparities
Key Themes:
- Disparities have complex, multifactorial origins.
- Biological differences include potentially different risk alleles in African American men.
- Social determinants of health significantly impact outcomes.
- Access to care, including clinical trials, remains problematic for Black men.
Key Points for Physicians:
- Consider biological and social factors when managing Black patients.
- Address potential socioeconomic barriers to treatment adherence.
- Facilitate clinical trial access when appropriate treatment options exist.
Notable Insights: The combination of biological differences and socioeconomic factors creates a complex landscape requiring multifaceted interventions at individual and systemic levels.
Clinical Significance: Understanding the interplay between biological and social factors is essential for developing effective strategies to reduce prostate cancer disparities in Black men.
Advertisement
Related to this article
Kiran Sury, MD, discusses patient selection, durability, and adverse events with ProACT for male stress urinary incontinence.
enGene expects to initiate a BLA submission by the end of 2026.
The designation was supported by findings from the phase 2 Co-PSMA trial, the phase 1/2 COBRA trial, and real-world evidence.
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
The updated guidance recommends routine PSA-based screening every 2 years for average-risk men aged 50 to 69 years and annual screening beginning at age 45 for Black men or men with a strong family history of prostate cancer.
Earlier genetic testing in men with very low sperm counts may spare unnecessary testing or surgery, according to Ronald Anglade, MD.
Vignesh Packiam, MD, discusses optimizing BCG treatment in high-risk NMIBC, including patient selection for combination immunotherapy and treatment-related trade-offs.
A national survey of US military service members and veterans with NMIBC found that more than half were diagnosed by age 50, while 63% reported treatment access barriers.
VOLGA results raise the question of treatment de-intensification in perioperative MIBC care, according to Suzanne B. Merrill, MD, FACS.
Advertisement
Advertisement
Trending on Urology Times
1
American Cancer Society updates prostate cancer screening guidelines, recommends regular PSA testing
2
FDA grants breakthrough therapy designation to 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging
3
BCG-naïve NMIBC: Optimizing initial treatment selection
4
FDA grants De Novo authorization to Virtuoso Robotic System for bladder tumor resection
5